Teva Pharmaceutical Industries (TEVA) Assets Average (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Assets Average came in at $39.9 billion in Q2 2026, up 1.72% YoY from $39.3 billion in Q2 2025, and down 1.1% on a QoQ basis from $40.4 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Assets Average (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Assets Average data on file, last reported at $39.9 billion in Q2 2026.
- Quarterly Assets Average rose 1.72% year-over-year to $39.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $39.9 billion (up 1.72% YoY) and the FY2025 annual result came in at $40.0 billion, down 3.3% from the prior year.
- Assets Average declined to $39.9 billion in Q2 2026, from $40.4 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $47.4 billion in Q1 2022 to a low of $38.9 billion in Q1 2025.
- A 5-year average of $42.3 billion and a median of $42.3 billion in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2025 — Assets Average declined 9.87% — and 2026, when it grew 3.92%.
- Tracing TEVA's Assets Average over 5 years: stood at $44.1 billion in 2022, then dropped by 3.05% to $42.8 billion in 2023, then declined by 5.25% to $40.5 billion in 2024, then decreased by 0.59% to $40.3 billion in 2025, then retreated by 0.88% to $39.9 billion in 2026.
- The last three Assets Average figures came in at $39.9 billion (Q2 2026), $40.4 billion (Q1 2026), and $40.3 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 5.97 Bn |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 4.33 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.95 Bn |
| Mar 31, 2026 | 40.39 Bn |
| Dec 31, 2025 | 40.30 Bn |
| Sep 30, 2025 | 39.99 Bn |
| Jun 30, 2025 | 39.27 Bn |
| Mar 31, 2025 | 38.87 Bn |
| Dec 31, 2024 | 40.54 Bn |
| Sep 30, 2024 | 41.55 Bn |
| Jun 30, 2024 | 42.06 Bn |
| Mar 31, 2024 | 43.13 Bn |
| Dec 31, 2023 | 42.79 Bn |
| Sep 30, 2023 | 42.60 Bn |
| Jun 30, 2023 | 43.28 Bn |
| Mar 31, 2023 | 43.74 Bn |
| Dec 31, 2022 | 44.13 Bn |
| Sep 30, 2022 | 45.09 Bn |
| Jun 30, 2022 | 46.50 Bn |
| Mar 31, 2022 | 47.36 Bn |
| Dec 31, 2021 | 47.76 Bn |
| Sep 30, 2021 | 48.52 Bn |